Market Overview

Analyst Remains Confident In Corium Despite Partner's Bad FDA News

Share:
Analyst Remains Confident In Corium Despite Partner's Bad FDA News
Related
Benzinga's Top Upgrades, Downgrades For October 15, 2018
44 Biggest Movers From Yesterday
Related AGRX
10 Hottest Stocks From October 16, 2018
10 Hottest Stocks From October 15, 2018

The U.S. Food and Drug Administration sent an unfavorable Complete Response Letter last week to Agile Therapeutics Inc (NASDAQ: AGRX) regarding approval for the Twirla contraceptive patch. The letter also included concerns at a third-party manufacturer, Corium International Inc (NASDAQ: CORI).

The Analyst

H.C. Wainwright & Co.'s Oren Livnat maintains a Buy rating on Corium's stock with a price target lowered from $15 to $14.

The Thesis

Agile's receipt of a Complete Response Letter was "surprising" given the therapy's robust clinical package and a "very compelling" risk-benefit profile, Livnat said in a Wednesday note. (See Livnat's track record here.) 

The deficiencies cited by the FDA were focused on the patch adhesion testing methods, manufacturing "483" observations at Corium and potential read-across of adhesion issues in the Twirla Phase 3 result, according to H.C. Wainwright. 

Systemic manufacturing issues at Corium are unlikely, and the problems are "few and minor," with no negative read-through to the company's patch technology platform or pipeline, Livnat said. 

The FDA's letter isn't a "deal breaker" for Twirla, the analyst said, and the FDA could approve the therapy in one year — but an FDA meeting scheduled for the first quarter of 2018 may accelerate the approval timeline.

The FDA letter's referernce to adhesion issues points to caution on the agency's part in making sure no issues specific to the patch result in higher pregnancy rates versus approved contraceptives, Livnat said. 

"Hopefully, Agile's detailed Phase data showing no correlation between adhesion and efficacy will quickly put the FDA's mind back at ease, and Twirla can be approved in 2018."

Price Action

Shares of Corium were trading slightly higher at $10.01 at the time of publication Wednesday.

Related Links:

Corium to Join NASDAQ Biotechnology Index

Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates

Latest Ratings for CORI

DateFirmActionFromTo
Oct 2018NeedhamDowngradesBuyHold
Oct 2018H.C. WainwrightDowngradesBuyNeutral
Sep 2017H.C. WainwrightInitiates Coverage OnBuy

View More Analyst Ratings for CORI
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News Price Target Reiteration FDA Analyst Ratings General Best of Benzinga

 

Related Articles (CORI + AGRX)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
AAPLWedbushInitiates Coverage On310.0
DHTJP MorganUpgrades0.0
DISBarclaysUpgrades130.0
DXCMGoldman SachsUpgrades125.0
ORLYJP MorganUpgrades398.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Didi Chuxing Is 'An Emerging Autonomous Superpower,' Says Morgan Stanley

Low Volume Marks Seasonal Trading; Stocks Struggle Early On